2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 3

The Presence of Rheumatoid Factor Is Associated with Lower Bone Mass in Korean Health Screening Male Subjects without Clinically Apparent Arthritis
Abstract Number: 2575

The Presence of Staphylococcal Toxins in the Urine of Patients with Rheumatoid Arthritis
Abstract Number: 2102

the Prevalence and Associations of IgG/a/M ANTI-β2GPI and ANTI-Domain I Antibodies in an Antiphospholipid Syndrome (APS) Cohort of Patients from Turkey
Abstract Number: 693

The Prevalence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review & Meta-Analysis
Abstract Number: 1295

The Prevalence of Inflammatory and Structural Lesions on MRI of the Sacroiliac Joints in Patients with Very Early Peripheral Spondyloarthritis
Abstract Number: 433

The Prevalence of Latent Tuberculosis and Hepatitis B Found after Systematic Screening of Patients Starting with Biological Therapy in a Low-Endemic Area
Abstract Number: 2495

The Prevalence of Loss of Response to Treatment with a Tumor Necrosis Factor Inhibitor and/or Methotrexate in Patients with Rheumatoid Arthritis
Abstract Number: 2453

The Prevention, Screening, and Treatment of Congenital Heart Block from Neonatal Lupus: A Survey of Provider Practices
Abstract Number: 1035

The Prognostic Value of Different Auto-Antibodies for Arthritis Development in Patients with Clinically Suspect Arthralgia
Abstract Number: 2588

The Real World Comparative Safety of Certolizumab Pegol (CZP) As Compared to Other TNFi in a National US Cohort
Abstract Number: 652

The Reasons for Discontinuation of Combination Therapy with Methotrexate and Tumor Necrosis Factor Inhibitors Versus Triple Therapy Differ Significantly Because of Higher Adverse Events with Triple Therapy
Abstract Number: 814

The Regulatory B Cells Ameliorate Skin Sclerosis, Lung Fibrosis, and Autoimmunity Via an Anti-Oxidative Effect in Systemic Sclerosis Model Mice
Abstract Number: 313

The Relation of Serum Urate to Radiographic Knee and Hand Osteoarthritis
Abstract Number: 345

The Relationship Between Anti-Cyclic Citrullinated Peptide (anti-CCP) Levels and Bone Mineral Density (BMD) or Fragility Fracture in Patients with Rheumatoid Arthritis (RA)
Abstract Number: 2338

The Relationship Between Anxiety and Physical Activity Participation in Adults with Persistent Knee Pain and the Moderating Effect of Neighborhood Social Cohesion

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].